Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Safety, tolerability and immunogenicity of V934/V935 hTERT vaccination in cancer patients with selected solid tumors: a phase I study

Fig. 3

Cell-mediated immune response to hTERT peptide pool 2 for the most frequent tumor types. Cell-mediated immunity response to hTERT pool 2 increased significantly (p < 0.01) in prostate cancer patients. No statistically significant response was observed in other tumor types (here malignant melanoma patients are pooled together with melanoma patients)

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us